Clinical Trial Update: A Multicenter Assessment of ALD403 in Frequent Episodic Migraine [Phase 3]

View source ↗

Summary

Phase 3 trial update for ALD403 in frequent episodic migraine completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• ALD403

Snippet

Sponsor: Alder Biopharmaceuticals, Inc. | Conditions: Migraine Disorders | Phase 3 | Status: COMPLETED | Results posted: 2020-05-14